Cutaneous sarcoidosis treated with medium-dose UVA1

Mahnke, Natalia; Medve-Koenigs, Kathrin; Berneburg, Mark; Ruzicka, Thomas; Neumann, Norbert

doi:10.1016/j.jaad.2003.09.027

Cited by 19 publications

(9 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[132][133][134] Ultraviolet A phototherapy also has been used with demonstrated improvement with 30 to 50 treatments. 135 With both photodynamic therapy and ultraviolet A phototherapy, risks include burning, erythema, and skin discomfort. Certain lasers have also been reported to be helpful for cutaneous sarcoidosis, with pulsed dye, CO 2 for laryngeal lesions, ruby, and potassium titanyl phosphate lasers being reported.…”

Section: Differential Diagnosismentioning

confidence: 99%

Cutaneous Sarcoidosis

Wanat

Rosenbach

2015

Clinics in Chest Medicine

View full text Add to dashboard Cite

The skin is the second most common organ affected in sarcoidosis, which can affect patients of all ages and races, with African American women having the highest rates of sarcoidosis in the United States. The cutaneous manifestations are protean and can reflect involvement of sarcoidal granulomas within the lesion or represent reactive non-specific inflammation, as seen with erythema nodosum. Systemic work-up is necessary in any patient with cutaneous involvement of sarcoidal granulomas, and treatment depends on other organ involvement and severity of clinical disease. Skin-directed therapies are first line for mild disease, and immunomodulators or immunosuppressants may be necessary.

show abstract

Section: Differential Diagnosismentioning

confidence: 99%

Cutaneous Sarcoidosis

Wanat

Rosenbach

2015

Clinics in Chest Medicine

View full text Add to dashboard Cite

show abstract

“…195 In few but noteworthy case reports, phototherapy had a beneficial effect. After a total dose of 2640 J/cm 2 of medium dose ultraviolet A1 (UVA1) given over 50 sessions, nearly complete resolution of plaque sarcoidosis involving 70% of the body surface was achieved without systemic medications, 196 whereas improvement but no resolution of papulonodular sarcoidosis in the forehead resulted from a UVA1 dose of 2460 J/cm 2 administered during 25 treatments. 197 In a small case series of 6 patients unresponsive to topical and systemic medications, there was complete resolution in 3 cases and 50% improvement in another 3 with a mean dose of 58.8 J/cm 2 given over a mean of 50 sessions.…”

Section: Other Pharmacologic Agentsmentioning

confidence: 99%

Sarcoidosis

Sanchez

Haimovic

Prystowsky

2015

Dermatologic Clinics

View full text Add to dashboard Cite

Sarcoidosis is a disease characterized by noncaseating granulomatous infiltration of 1 or more organs. In North America, after the lungs and thoracic lymph nodes, the skin is the next most commonly involved organ. Data from multiple studies indicate a coaction between genetic and environmental factors in immunologically susceptible hosts. The disease's many clinical manifestations and course vary greatly and are influenced by race, ethnicity, and gender. In the skin, the lesions of sarcoidosis are classified as specific when noncaseating granulomas are present, and nonspecific when there is an inflammatory reaction pattern devoid of granulomas.

show abstract

“…Ultraviolet phototherapy. There are sporadic case reports on the effect of ultraviolet (UV) A1 phototherapy in sarcoidosis skin lesions arguing that some immunomodulating effects have been shown by UVA1 administration [52]. However, long-term risks, such as carcinogenic ones, have to be taken into account.…”

Section: Other Skin Lesionsmentioning

confidence: 99%

Skin manifestations in sarcoidosis

Eklúnd¹,

Rizzato²

2005

Sarcoidosis

View full text Add to dashboard Cite

Almost a century ago, the relationship of sarcoid infiltrations of the skin and granulomatous changes in other organs was recognised. Schaumann, in 1914, proposed that lupus pernio (fig. 1a-c) could be a manifestation of a generalised disease. Later on, a variety of skin manifestations have been described to occur more or less frequently. Lupus pernio indicates an unfavourable prognosis, whereas in the case of erythema nodosum (EN) (fig. 2), disease remission generally occurs within months or a few years [1-4]. The histopathological characteristics of the two findings are totally different, reflecting the variable clinical picture and outcome in this inflammatory disorder where the antigen(s) still are unknown [5, 6]. Beside these two extremes, there are a number of other more or less common skin lesions having either a maculopapular, subcutaneous, cicatricial or plaque character. In this chapter, a sharp distinction will be made between nonspecific lesions, i.e. erythema nodosum, and specific skin manifestations, e.g. lupus pernio. The frequency of skin lesions in sarcoidosis varies depending on the intensity by which they are looked for [7, 8], as well as on the ethnic background of the patients [5, 6]. In Scandinavia, about one-third of the patients born there will present with EN as part of Lö fgren's syndrome [2]. However, in Japanese patients, this syndrome is less common. In contrast, lupus pernio is very infrequent in Scandinavia, but more common among African Americans in the USA [5, 6]. On an average, y25% of sarcoidosis cases have cutaneous involvement, which may appear at any stage of the disease [5, 9, 10]. More recently, Yanardag et al. [7] reported a higher percentage (almost 33%) of skin manifestations among w500 Turkish patients. Roughly, 20% of them had EN. The frequency of reported specific cutaneous involvement in sarcoidosis ranges from 10-40%.

show abstract

Cutaneous sarcoidosis treated with medium-dose UVA1

Cited by 19 publications

References 5 publications

Cutaneous Sarcoidosis

Cutaneous Sarcoidosis

Sarcoidosis

Skin manifestations in sarcoidosis

Contact Info

Product

Resources

About